Engflag

Alorica

Quick links to important sections

Alorica

Alorica_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alorica

Property Description
Active ingredient Allopurinol
Form Oral tablet, Powder for injection
Pharmacological class Xanthine Oxidase Inhibitor (XOI)
Common use Reducing elevated uric acid levels
Origin Synthetic purine base analogue

What Type of Medicine is Alorica?

Alorica is a prescription medication chemically defined by its active ingredient, Allopurinol, and belongs to the pharmacological class of Xanthine Oxidase Inhibitors (XOI). This class is formally known as antihyperuricemic agents, signifying their purpose is to reduce excessive levels of uric acid in the bloodstream. Allopurinol is classified as a synthetic purine base analogue, a man-made compound structurally similar to hypoxanthine, a natural purine found in the body. Its role is clinically recognized for providing the foundational, long-term therapeutic control required in patients managing chronic hyperuricemia.

Composition and Available Forms

The medication is comprised solely of the active ingredient Allopurinol, combined with non-therapeutic excipients for oral use or a sterile base for injection. Alorica is most commonly dispensed as an oral tablet for routine daily use, representing the standard route of administration for maintenance therapy. It is also supplied as a sterile powder for injection, which is reconstituted into a solution intended for intravenous administration in specialized acute clinical situations where immediate intervention is necessary or where oral intake is not possible. This versatility in dosage forms is a differentiating factor, supporting flexible therapeutic strategies.

How Alorica Works to Reduce Uric Acid

The core purpose of Alorica is to prevent the body from producing excessive amounts of uric acid by halting a key step in purine metabolism. It achieves this by selectively binding to and blocking the enzyme xanthine oxidase (XO), which is the enzyme responsible for converting other purine compounds into uric acid. This inhibition ensures that the overall burden of uric acid production is significantly lowered. Allopurinol is highly effective in achieving and maintaining low and stable serum urate concentrations, which is the foundational therapeutic goal of this medication in long-term care.

Regulatory References

  1. NIH - Allopurinol LiverTox

What side effects are possible with Alorica?

Possible Side Effects and Safety Information

The safety profile of Alorica, chemically Allopurinol, involves adverse reactions that are classified by frequency and affect various physiological systems. The most common reported effects include skin rash, nausea, vomiting, diarrhea, and elevations in liver function tests, as documented in official regulatory labeling.

Serious Adverse Reactions and Systemic Risk

Serious, though rare, adverse reactions are officially documented. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). Additionally, safety labeling addresses potential adverse effects on the blood and lymphatic system, including myelosuppression (bone marrow suppression), and the hepatobiliary and renal systems, which may present as hepatotoxicity or renal failure/insufficiency.

Safety Constraints and Population Risk Factors

Certain constraints and population-specific risks are noted in the regulatory documents. Treatment must be permanently discontinued immediately upon the first appearance of a skin rash or other sign of a hypersensitivity reaction. Acute attacks of gout (gout flares) are reported to occur during the early stages of administration, as urate is mobilized. Individuals with impaired renal function are at a higher risk of toxicity and hypersensitivity, and dosage modification is often required. Furthermore, patients carrying the *HLA-B58:01 allele** are documented to have a substantially increased risk of developing SCARs.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Allopurinol (Alorica) strictly defines the symptoms and the mandated response for overdosage.

Overdose Scope: Documented Presentations Acute overdosage has been officially associated with significant gastrointestinal symptoms, including nausea, vomiting, and diarrhea. The primary systemic risk is to the renal system, where the deposition of xanthine crystals can lead to obstructive nephropathy and subsequent severe renal impairment or renal failure. Extended hospital observation and monitoring may be required following overdosage due to the delayed potential for this serious renal complication.

Emergency Response and Management Regulatory guidance is explicit: immediate medical attention must be sought for any suspected overdose. For cases of massive ingestion, individuals must contact emergency services without delay. Treatment is documented as symptomatic and supportive, emphasizing that no specific antidote is known. Procedural interventions, such as the use of hemodialysis, have been utilized in clinical settings to effectively remove the compound and its active metabolite from the circulation. The official labeling specifies this need for aggressive supportive care.

Therapeutic Uses of Alorica

Therapeutic Indications

Alorica is primarily utilized in the management of chronic conditions associated with elevated levels of uric acid in the bloodstream. By addressing the underlying metabolic imbalance, it helps prevent the accumulation of urate crystals in the joints and tissues.

Management of Gout

The most common application of this medication is for the long-term treatment of gout. Gout is a form of inflammatory arthritis characterized by the deposition of monosodium urate crystals. Alorica works to lower serum urate levels, which helps to:

  • Decrease the frequency of acute gout flares.
  • Prevent the formation of tophi, which are permanent deposits of urate crystals under the skin.
  • Reduce the risk of progressive joint damage and chronic inflammation.

Prevention of Uric Acid Nephropathy

In addition to joint health, Alorica is used to protect renal function in individuals predisposed to high uric acid levels. This includes the prevention of uric acid stones in the urinary tract and the management of uric acid nephropathy, a condition where crystals can impair kidney function.

Secondary Hyperuricemia

Alorica may also be indicated for individuals experiencing secondary hyperuricemia. This occurs when elevated uric acid levels are a consequence of other underlying conditions or certain medical treatments that cause a rapid breakdown of cells, leading to a surge of uric acid in the systemic circulation.

Benefits and Long-term Goals

The primary objective of treatment with Alorica is the maintenance of stable, low uric acid levels. Unlike treatments focused on immediate pain relief during an attack, Alorica provides long-term systemic benefits:

  • Crystal Dissolution: By maintaining low serum urate levels, existing crystal deposits can gradually dissolve over time.
  • Joint Preservation: Consistent management helps prevent the erosive changes in bone and cartilage associated with chronic gout.
  • Metabolic Stability: It assists in regulating the body's chemical balance for individuals who overproduce uric acid or have difficulty excreting it naturally.

Eligibility and Restrictions for Use

The drug product referred to as "Alorica" is addressed here based on the established regulatory profile of Absorica (isotretinoin), a highly restricted medication in the United States. Eligibility is strictly defined by governmental regulatory documents.

Official Eligibility

Classification Eligible Population Restriction/Condition
Allowed Non-pregnant patients, 12 years of age and older Treatment of severe recalcitrant nodular acne (unresponsive to conventional therapy, including systemic antibiotics).
Contraindicated Patients who are pregnant, or may become pregnant High risk of severe, life-threatening birth defects (Embryo-Fetal Toxicity).
Contraindicated Patients with known hypersensitivity Allergic reaction to isotretinoin or any of its components.

Use Restrictions and Special Considerations

The medicine is reserved for patients who meet the specific disease criteria and who fully comply with the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program. All patients, including male patients, must be enrolled and adhere to the program’s requirements for safe use and distribution.

  • Pregnancy/Lactation: Use is contraindicated in pregnancy. Breastfeeding is not recommended during therapy and for a short period after discontinuation, due to the potential for serious adverse reactions in the nursing infant.
  • Concomitant Use: Use with tetracyclines must be avoided due to the risk of intracranial hypertension (pseudotumor cerebri).
  • Age: Safety and effectiveness have not been established in pediatric patients under 12 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Allopurinol's official interaction profile is defined by its role as an enzyme inhibitor, affecting the metabolism and clearance of co-administered medications. Certain combinations are subject to specific regulatory constraints documented in prescribing information.

Contraindicated and High-Risk Combinations:

  • Co-administration with Pegloticase is restricted; Allopurinol therapy must be discontinued before beginning Pegloticase treatment.
  • Use with Capecitabine should be avoided due to the potential for increased toxicity.
  • The systemic exposure of Mercaptopurine and Azathioprine is significantly increased, requiring a mandatory regulatory adjustment where the dose of the co-administered drug must be reduced to approximately one-third to one-fourth of the usual dose.

Exposure and Effect Modification:

  • Allopurinol may inhibit the metabolism of oral anticoagulants such as Warfarin, potentially enhancing the anticoagulant effect.
  • The plasma concentrations of several other medicines, including Cyclosporine, Vidarabine, and Phenytoin, may be increased when co-administered, necessitating close monitoring.
  • Uricosuric agents (e.g., Probenecid) may accelerate the excretion of Allopurinol’s active metabolite, which can reduce its effectiveness.

Timing and Substance Constraints:

  • Aluminum Hydroxide may reduce Allopurinol absorption and must be administered with a 3-hour gap to prevent this interaction.
  • Co-administration with ACE inhibitors or thiazide diuretics carries an increased risk of hypersensitivity reactions, a caution noted specifically for patients with decreased renal function.
  • Consumption of alcohol may counteract the therapeutic effect by increasing uric acid levels.

Mechanism of Action

Selective Receptor Signaling Modulation

This mechanistic domain covers the molecule’s ability to selectively bind to specific cell surface receptors, initiating or blocking signals at a molecular level. This targeted interaction modifies activity in overactive or dysregulated cellular pathways and is linked to modulation of baseline physiological responses.

Influence on Core Enzyme-Driven Pathways

The drug's mechanism engages critical enzyme systems, acting as an inhibitor or a modulator to alter the production or metabolism of key signaling mediators. By controlling the supply of these mediators, the molecule alters activity within pathways associated with heightened physiological responses.

The Cascade to Systemic Adjustment

The molecule’s local action triggers a cascade: molecular binding leads to altered cellular signal transduction, which then translates into modified tissue-level behavior. This systematic sequence of events influences key central and/or peripheral regulatory systems, which results in measurable alterations to systemic activity.

Dosage and Administration Information

Alorica is utilized through two approved administration routes, which depend on the clinical context: the oral tablet is the standard for long-term, chronic management, while the intravenous (IV) infusion is reserved for acute situations or for patients unable to take the medicine orally.

For chronic management, the usual oral therapy begins at a low daily starting dose, typically 100 mg. The dosage is not fixed but requires titration (gradual adjustment), often in 100 mg increments on a weekly basis, until the individual's target serum urate concentration is reached. The maximum labeled dose for adults is 800 mg daily.

Proper oral administration includes specific contextual conditions. The tablets are generally taken following a meal to enhance gastrointestinal tolerability. A mandatory requirement for adults on this medication is maintaining adequate fluid intake to achieve a daily urine output of at least 2 liters. Furthermore, any total daily oral dose exceeding 300 mg must be divided and taken at separate times during the day.

A mandatory dose reduction is specified for patients with kidney (renal) impairment. For these patients, the initial dose may be as low as 50 mg daily, with subsequent adjustments based on the degree of reduced renal function. In cases of prophylactic use for chemotherapy-related hyperuricemia, administration should be initiated 24 to 48 hours prior to the start of the cancer treatment. If a dose is missed, patients are instructed not to double the next dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Alorica (Allopurinol)

Evidence for Use in Chronic Gout Management and Hyperuricemia

The research exploring Alorica in long-term gout management includes short-term Randomized Controlled Trials (RCTs) and long-term observational studies. Researchers used these studies to examine how the medicine was associated with serum urate (SU) concentrations. Studies monitored adults with established gout, including those with joint damage and varying degrees of kidney function. Studies conducted over defined time intervals monitored changes in SU levels, while long-term observational data explored the patterns of gout flare frequency and examined changes in the size and presence of tophi.

It is not yet clear whether achieving the target SU concentration has an immediate, direct correlation with a rapid change in gout flare incidence; findings were mixed in some initial trials. Furthermore, evidence describing sustained changes in daily functioning often relies on observational designs.

Evidence for Use in Cancer Therapy-Related Conditions

Alorica was evaluated in research exploring high uric acid levels that may arise during certain cancer treatments, such as chemotherapy-induced hyperuricemia. The research examined for this clinical situation includes controlled trials and post-marketing analyses, often focusing on the intravenous form in acute settings. Studies monitored changes in acute serum uric acid concentrations, with documented outcomes evaluating the incidence of severe complications like acute uric acid nephropathy. Evidence is limited in the form of large, contemporary placebo-controlled RCTs, as its use in this acute setting is an established practice.

Areas of Research Uncertainty

The research landscape contains areas where certainty remains low or evidence is still emerging. Data for certain groups, such as those with multiple co-occurring conditions, remain insufficient for generalized conclusions. Follow-up durations were limited in many initial RCTs, meaning long-term outcomes remain uncertain through the same level of rigorous evidence available for the initial stabilization phase. Findings were mixed in some studies regarding the short-term clinical outcomes compared to the established biochemical effects.

Key Studies & References

  1. Tumor Lysis Syndrome (TLS) in Adult Patients - MD Anderson Cancer Center Clinical Algorithm (Prophylaxis with Allopurinol)

Frequently Asked Questions (FAQ)

Common questions about Alorica (FAQ)

Q: What is the main reason doctors prescribe Alorica?

The medicine is primarily prescribed for the long-term control of hyperuricemia, which means reducing excessive levels of uric acid in the bloodstream. This is the underlying condition that causes gout. Official product information also describes its use in certain circumstances to prevent high uric acid levels in patients undergoing specific cancer treatments.

Q: How quickly can a person generally expect Alorica to start working?

Studies indicate that it may take several months of therapy to observe the full effect of the medicine on the body's total uric acid levels and related conditions. The most significant measurable decrease in serum uric acid levels is generally observed within the first few months after starting therapy.

Q: Do you have to take Alorica at the same time every day?

Official patient instructions suggest taking the medicine at the same time every day to help maintain consistent levels in the body. For higher total daily amounts, regulatory guidance requires the dose to be split and taken at separate times throughout the day.

Q: Is Alorica considered a long-term medication?

For gout management, the medicine is described in official documents as suitable for long-term, chronic management. Its use is continued to maintain stable, low uric acid levels. In contrast, its use for managing uric acid levels during cancer therapy is generally intended for a temporary course.

Q: What if I forget to take my Alorica?

General guidance indicates that if a dose is missed, it can be taken as soon as it is remembered, unless it is near the time for the next scheduled dose. Regulatory instructions are clear that the next dose should never be doubled to make up for the missed one.

Q: Is Alorica known to be habit-forming or addictive?

The medicine is classified as a non-controlled substance by regulatory bodies. Official documents indicate that it has no known potential for abuse or dependence based on its pharmacological class and clinical profile.

Q: What is the difference between Alorica and a supplement?

Alorica (Allopurinol) is a prescription-only medication that is strictly regulated and must be authorized by a licensed healthcare professional. Supplements are products that are not regulated by the FDA as drugs and do not require a prescription.

Q: Can I take Alorica if I am allergic to penicillin?

Official information lists hypersensitivity to the active ingredient, Allopurinol, or any of its components as a contraindication. Regulatory documents are silent regarding a specific contraindication based on a cross-allergy to penicillin. Hypersensitivity to the active ingredient remains the primary concern.

Q: How often are people usually monitored while taking Alorica?

Regulatory documents recommend monitoring the patient’s kidney and liver function during the initial stages of administration. Monitoring of serum uric acid levels is also a key part of treatment to ensure the medicine is achieving its goal.

Q: What are the most common reasons people switch from Alorica to another medicine?

The medicine is generally discontinued upon the appearance of a skin rash or other signs of a hypersensitivity reaction, as noted in regulatory documents. Other documented reasons for discontinuation or switching include difficulty in reaching the target uric acid level or the development of adverse effects on the liver or kidneys.

Q: Is Alorica commonly prescribed for people over 65?

While older patients have been included in clinical experience, official documents note that they are more likely to have decreased kidney function. Because of this, official information suggests careful consideration of the starting dose, as older patients may require dosage adjustment due to decreased kidney function.

Q: What is the chemical name for Alorica?

The active ingredient is Allopurinol. Regulatory and chemical documents describe it as a synthetic purine base analogue, with the more formal chemical name being 1H-Pyrazolo[3,4-d]pyrimidin-4-ol.

Q: Does taking Alorica make you more sensitive to the sun?

Yes, regulatory product information in some countries lists photosensitivity as a reported adverse reaction. This describes an increased sensitivity to light, particularly sunlight, in some individuals.

Q: Is Alorica available as a liquid or only as a pill?

The medicine is commercially supplied as an oral tablet and a powder for injection intended for intravenous use in acute settings. A ready-to-use liquid formulation may be available through specialized compounding pharmacies, but it is not a standard commercial product.

Q: Is Alorica recommended for everyone with the condition it treats?

No. The medicine is contraindicated for anyone with a known hypersensitivity to the active ingredient. Furthermore, official labeling advises a mandatory dosage reduction for patients with decreased kidney function due to the increased risk of toxicity.

Q: Does Alorica need a special prescription or can it be obtained over the counter?

The medicine is classified as a prescription-only drug by regulatory agencies. It cannot be obtained over the counter (OTC) and must be prescribed by a licensed healthcare professional.

Q: Is it possible to take Alorica with a vitamin D supplement?

No direct interactions between the medicine and Vitamin D supplements are listed in the official regulatory documents. General guidance in drug information states that patients should inform their healthcare professional of all supplements they are taking.

Q: Can Alorica affect the results of a blood test?

Yes. Regulatory documents note that the medicine can be associated with adverse effects on the liver, which may show up as elevated liver function tests. There is also a potential for effects on the blood and lymphatic system, which can be detected during routine blood monitoring.

Q: Are there any restrictions on driving or operating machinery while taking Alorica?

Official labeling includes a warning that if drowsiness, somnolence, or dizziness occur, activities requiring mental alertness, such as driving or operating hazardous machinery, should be avoided.

Q: Why do some people say Alorica made them feel dizzy?

Official labeling lists dizziness and somnolence (drowsiness) as possible adverse reactions that have been reported with the use of the medicine. These are noted as potential effects on the central nervous system.

Q: Does Alorica affect sleep patterns?

The official labeling does not specifically reference 'sleep patterns,' but it does note the potential for central nervous system effects such as drowsiness and somnolence.

How should Alorica be stored and disposed of?

How to Store and Dispose of Alorica?

Alorica (Allopurinol) storage and disposal must strictly follow the requirements set by official regulatory labeling, which address environmental conditions, stability, and child safety.

Official Storage and Handling

Item Requirement(s)
Oral Tablets Store at room temperature, typically below 25 C (77 F), protected from excess heat, moisture, and freezing.
Packaging Keep the medication in the original, tightly closed container.
Injection Solution The reconstituted solution must not be refrigerated and must be administered within 10 hours of preparation; any unused portion must be discarded.
Child Safety Keep all forms of the medicine out of the sight and reach of children.

Official Disposal Protocol

Unused or expired Alorica should be disposed of through a dedicated drug take-back program or mail-back service. If these options are unavailable, the official guidance permits disposal in household trash after mixing the product with an undesirable substance, such as coffee grounds, and placing it in a sealed container. Furthermore, official regulations strictly mandate that the product must not enter drains or water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Alorica found in:

A-Z Index: